7,7-diphenyl-6-heptenoic acid | 122213-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7,7-diphenyl-6-heptenoic acid
• 英文别名: 7,7-diphenylhept-6-enoic acid；7,7-diphenyl-hept-6-enoic acid；7,7-Diphenyl-hept-6-ensaeure；7,7-Diphenyl-hepten-(6)-saeure
• CAS: 122213-92-7
• 化学式: C₁₉H₂₀O₂
• 分子量: 280.367
• InChiKey: DKGSOSXANWHAIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7,7-diphenyl-6-heptenoic acid 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以84%的产率得到7,7-diphenyl-6-heptenol
  参考文献：
  名称：

  通过β-甲磺酸酯基的异源裂解有效生产烯醇醚自由基阳离子。

  摘要：

  [反应：见正文]在激光闪光光解反应中产生了α-甲氧基-β-甲氧基，并测定了由甲磺酸酯基的杂化断裂形成的烯醇醚自由基阳离子的收率。甲磺酸盐的杂合反应比类似基团中的磷酸酯和溴化物基团的杂合反应快，并且在中极性溶剂中非常高效。

  DOI：

  10.1021/ol034061o
• 作为产物：
  描述：

  7,7-diphenyl-hept-6-enenitrile 在 氢氧化钾 、 二乙二醇 作用下， 生成 7,7-diphenyl-6-heptenoic acid
  参考文献：
  名称：

  THE ATTEMPTED BECKMANN REARRANGEMENT OF 2,2-DIPHENYL-1-CYCLOHEPTANONE OXIME¹

  摘要：

  DOI：

  10.1021/jo01123a011

文献信息

• Pyridine compounds which are useful in treating a disease state
  申请人：Hoffman-La Roche Inc.

  公开号：US04927838A1

  公开（公告）日：1990-05-22

  The invention relates to compounds of the formula ##STR1## wherein Y and Y' are hydrogen or taken together are O or S, *A is paraphenylene or *----(CH.sub.2).sub.n --(X).sub.s --(CH.sub.2).sub.r ----, X is O, S or --CH.dbd.CH--, n or r, independently, are integers from 0 to 3, m is an integer from 0 to 1, s is an integer from 0 to 1, provided that when s is 1, n+m must be at least 2, t is an integer from 0 to 10, R.sub.1 and R.sub.2, independently, are lower alkyl, lower alkenyl or aryl, or one of R.sub.1 or R.sub.2 is hydrogen and the other is ##STR2## wherein W is ##STR3## --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --, O, S, or ##STR4## and X.sub.1 is lower alkyl, phenyl unsubstituted or mono-, di- or trisubstituted by lower alkoxy, lower alkyl or halogen, and X.sub.2, X.sub.3 and X.sub.4, independently, are hydrogen, lower alkyl, lower alkoxy or halogen, R.sub.3 is hydrogen, lower alkyl or aryl, R.sub.4 is hydrogen, lower alkyl, aryl, aryl-lower alkyl or acyl, R.sub.5 is hydrogen or lower alkyl, R.sub.6 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 6-membered heteroaromatic radical containing one or two nitrogen atoms, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R.sub.5 and R.sub.6 are different, their enantiomers and racemic mixtures thereof, when R.sub.1 and R.sub.2 are different, their geometric isomers, and pharmaceutically acceptable acid addition salts thereof.

  该发明涉及以下式的化合物##STR1##其中Y和Y'是氢或一起取O或S，*A是对苯二甲基或*----(CH.sub.2).sub.n --(X).sub.s --(CH.sub.2).sub.r ----，X是O、S或--CH.dbd.CH--，n或r独立地是0到3的整数，m是0到1的整数，s是0到1的整数，但当s为1时，n+m必须至少为2，t是0到10的整数，R.sub.1和R.sub.2独立地是较低的烷基、较低的烯烃基或芳基，或者R.sub.1或R.sub.2中的一个是氢，另一个是##STR2##其中W是##STR3##--CH.sub.2 --CH.sub.2 --，--CH.sub.2 --，O，S，或##STR4##，X.sub.1是较低的烷基，苯基未取代或被较低的烷氧基、较低的烷基或卤素单取代、双取代或三取代，X.sub.2、X.sub.3和X.sub.4独立地是氢、较低的烷基、较低的烷氧基或卤素，R.sub.3是氢、较低的烷基或芳基，R.sub.4是氢、较低的烷基、芳基、芳基-较低的烷基或酰基，R.sub.5是氢或较低的烷基，R.sub.6是氢、较低的烷基、环烷基、Het-较低的烷基或芳基，Het是含有一个或两个氮原子的单环6-成员杂芳基，该基团可以被较低的烷基、卤素或芳基取代，星号表示连接点，当R.sub.5和R.sub.6不同时，它们的对映异构体和外消旋混合物，当R.sub.1和R.sub.2不同时，它们的几何异构体，以及其药学上可接受的酸盐。
• A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis
  作者：Gloria Hernández-Torres、Mariateresa Cipriano、Erika Hedén、Emmelie Björklund、Ángeles Canales、Debora Zian、Ana Feliú、Miriam Mecha、Carmen Guaza、Christopher J. Fowler、Silvia Ortega-Gutiérrez、María L. López-Rodríguez

  DOI：10.1002/anie.201407807

  日期：2014.12.8

  of MAGL inhibitors are needed to validate this enzyme as a therapeutic target. Here we report a potent, selective, and reversible MAGL inhibitor (IC50=0.18 μM) which is active in vivo and ameliorates the clinical progression of a multiple sclerosis (MS) mouse model without inducing undesirable CB1‐mediated side effects. These results support the interest in MAGL as a target for the treatment of MS

  单酰基甘油脂酶（MAGL）是负责内源性大麻素2-花生四烯酸甘油酯（2-AG）失活的酶。MAGL抑制剂在几种疾病模型中均具有镇痛和组织保护作用。然而，迄今为止描述的几种有效且选择性的MAGL抑制剂不可逆地阻断了该酶，并且这可能导致药理学耐受性。因此，还需要其他类别的MAGL抑制剂来验证该酶是否可作为治疗靶标。此处我们报告一个有效的，选择性，和可逆的抑制剂MAGL（IC 50 = 0.18μ中号），它是体内活性和改善多发性硬化（MS）的小鼠模型的临床进展，而不引起不希望的CB 1介导的副作用。这些结果支持了对MAGL作为MS治疗靶标的兴趣。
• Carboxylate-Substituted Radicals from Phenylselenide Derivatives. Designs on Models for Coenzyme B₁₂-Dependent Enzyme-Catalyzed Rearrangements
  作者：Neil Miranda、Pierre Daublain、John H. Horner、Martin Newcomb

  DOI：10.1021/ja034888d

  日期：2003.5.1

  beta-phenylselenyl esters, carboxylic acids, and carboxylates in aqueous acetonitrile media gave the corresponding radicals by homolytic cleavage of the phenylselenyl groups. In the beta-substituted systems, acid and carboxylate radicals reacted in intramolecular reporter reactions with approximately equal rate constants. For the alpha-substituted systems, an ester- and carboxylic acid-substituted radical

  α-和β-苯基硒基酯、羧酸和羧酸盐在乙腈水溶液中的激光闪光光解 (266 nm) 通过苯基硒基的均裂裂解产生相应的自由基。在β-取代系统中，酸和羧酸根在分子内报告分子反应中以大约相等的速率常数进行反应。对于 α-取代系统，酯和羧酸取代的自由基在分子内报告反应中以相同的速率常数反应，但类似的 α-羧酸根，自由基阴离子，反应速度要慢一个数量级，并且与比类似物的活化能高 3 kcal/mol。平衡α-酸和α-羧酸根的动力学滴定得到pKa = 4.6。
• [3]Foldarotaxane-mediated synthesis of an improbable [2]rotaxane
  作者：Victor Koehler、Maxime Gauthier、Chenhao Yao、Karine Fournel-Marotte、Philip Waelès、Brice Kauffmann、Ivan Huc、Frédéric Coutrot、Yann Ferrand

  DOI：10.1039/d2cc03066g

  日期：——

  an aromatic oligoamide helix around an active ester-containing [2]rotaxane enforced the sliding and the sequestration of the surrounding macrocycle around a part of the axle for which it has no formal affinity. The foldamer-mediated compartmentalization of the [2]rotaxane shuttle was subsequently used to prepare an improbable rotaxane.

  将芳族低聚酰胺螺旋缠绕在含活性酯的 [2] 轮烷周围，使周围的大环在没有正式亲和力的部分轴周围滑动和隔离。[2] 轮烷穿梭的折叠体介导的区室化随后用于制备不太可能的轮烷。
• Substituted alkene carboxylic acid amides and derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0298466A2

  公开（公告）日：1989-01-11

  There are described compounds of the general formula wherein Y and Y′ are hydrogen or taken together are O or S, *A is paraphenylene or *-(CH₂)n-(X)s-(CH₂)r-, X is O, S or -CH=CH-, n and r, independently are integers from 0 to 3, m is the integer 0 or 1, s is the integer 0 or 1, provided that when s is 1, n+m is at least 2, t is an integer from 0 to 10, R₁ and R₂, independently, are lower alkyl, lower alkenyl or aryl, or one of R₁ and R₂ is hydrogen and the other is W is -CX₃=CX₄-, -CH₂-CH₂-, -CH₂-, O, S or -NX₅-, X₁ is lower alkyl, phenyl or phenyl with up to 3 substituents selected from lower alkoxy, lower alkyl and halogen, X₂, X₃ and X₄, independently, are hydrogen, lower alkyl, lower alkoxy or halogen, X₅ is lower alkyl, R₃ is hydrogen, lower alkyl or aryl, R₄ is hydrogen, lower alkyl, aryl, aryl-lower alkyl or acyl, R₅ is hydrogen or lower alkyl, R₆ is hydrogen,     lower alkyl, lower cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 6-membered heteroaromatic radical containing one or two nitrogen atoms, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, when R₅ and R₆ are different, enantiomers and racemic mixtures thereof, when R₁ and R₂ are different, geometric isomers thereof, and pharmaceutically acceptable acid addition salts thereof. These compounds exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shocks or transplant rejections.

  所述化合物通式如下 其中 Y 和 Y′为氢或合起来为 O 或 S，*A 为对苯二甲酸或 *-(CH₂)n-(X)s-(CH₂)r-，X 为 O、S 或-CH=CH-，n 和 r 独立地为 0 至 3 的整数，m 为 0 或 1 的整数、s 是 0 或 1 的整数，条件是当 s 为 1 时，n+m 至少为 2，t 是 0 至 10 的整数，R₁ 和 R₂ 独立地是低级烷基、低级烯基或芳基，或者 R₁ 和 R₂ 中的一个是氢，另一个是 W 是-CX₃=CX₄-、-CH₂-CH₂-、-CH₂-、O、S 或-NX₅-，X₁ 是低级烷基、苯基或带有最多 3 个选自低级烷氧基、低级烷基和卤素的取代基的苯基，X₂、X₃ 和 X₄ 独立地、是氢、低级烷基、低级烷氧基或卤素，X₅ 是低级烷基，R₃ 是氢、低级烷基或芳基，R₄ 是氢、低级烷基、芳基、芳基-低级烷基或酰基，R₅ 是氢或低级烷基，R₆ 是氢、 R₅是氢或低级烷基，R₆是氢、低级烷基、低级环烷基、Het-低级烷基或芳基，Het 是含有一个或两个氮原子的单环六元杂芳基，该基可被低级烷基、卤素或芳基取代，星号表示连接点、 当 R₅ 和 R₆ 不同时，其对映体和外消旋混合物；当 R₁ 和 R₂ 不同时，其几何异构体；以及其药学上可接受的酸加成盐。 这些化合物具有血小板活化因子（PAF）拮抗剂的活性，因此可用于以血小板活化因子过量为特征的疾病状态，或用于预防和治疗心血管疾病、肺部疾病、免疫性疾病、炎症性疾病、皮肤病、休克或移植排斥反应。